2'-c-methyladenosine profile

2'-C-methyladenosine: antiviral [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	500900
CHEMBL ID	73809
SCHEMBL ID	382543
MeSH ID	M0570237

Synonym
2-c-methyl adenosine
2'-methyl-adenosine
2'-c-methyladenosine
2'-c-methyl adenosine
CHEMBL73809 ,
beta-2'-methyladenosine
(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-3,4-diol
2'-c-methyl-adenosine
bcx-4026
2'-c-mea
2'-c-ch3-a
(3r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
2'-c-me-a
2''-c-methyladenosine
(2r,3r,4r,5r)-2-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-3,4-diol
2''-methyl-adenosine
bdbm50144948
(2r,3r,4r,5r)-5-hydroxymethyl-3-methyl-2-(6-methylamino-purin-9-yl)-tetrahydro-furan-3,4-diol
beta-2''-methyladenosine
(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
15397-12-3
AKOS015914550
(2r,3r,4r,5r)-2-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol
PASOFFRBGIVJET-YRKGHMEHSA-N
SCHEMBL382543
DTXSID90333334
2/'-c-methyladenosine
mfcd02682944
F12904
BS-25234
PD077382
2-c-methyladenosine

Excerpt	Reference	Relevance
" 2'-C-Methyladenosine was found to be susceptible to enzymatic conversions by adenosine deaminase and purine nucleoside phosphorylase, and it displayed limited oral bioavailability in the rat."	( Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. Ball, RG; Bennett, CF; Bera, S; Bhat, B; Bhat, N; Bosserman, M; Brooks, J; Burlein, C; Carroll, SS; Colwell, LF; Cook, PD; Dande, P; Eldrup, AB; Fay, JF; Flores, OA; Getty, K; LaFemina, RL; Leone, J; MacCoss, M; McMasters, DR; Olsen, DB; Prakash, TP; Prhavc, M; Song, Q; Tomassini, JE; Von Langen, D; Wolanski, B, 2004)	1.23
" The oral bioavailability of the initial lead was below 5%; therefore, additional analogues were synthesized and screened for liver NTP levels after oral administration to rats."	( Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection. Boyer, SH; Erion, MD; Fujitaki, JM; Hecker, SJ; Huang, W; Koeplinger, KA; Linemeyer, DL; MacCoss, M; Olsen, DB; Reddy, KR; Reddy, MV; Sun, Z; van Poelje, PD; Varkhedkar, V, 2007)	0.64

Excerpt	Relevance	Reference
" Lead compounds identified in a primary rat hepatocyte screen were shown to result in liver levels of NTP predictive of efficacy after intravenous dosing to rats."	( Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection. Boyer, SH; Erion, MD; Fujitaki, JM; Hecker, SJ; Huang, W; Koeplinger, KA; Linemeyer, DL; MacCoss, M; Olsen, DB; Reddy, KR; Reddy, MV; Sun, Z; van Poelje, PD; Varkhedkar, V, 2007)	0.64

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A1	Rattus norvegicus (Norway rat)	Ki	0.7400	0.0001	1.2092	9.9700	AID31854
Adenosine receptor A1	Bos taurus (cattle)	Ki	0.9300	0.0000	0.7131	6.0000	AID239456; AID32002
Adenosine receptor A2a	Homo sapiens (human)	Ki	4.6100	0.0000	1.0609	9.7920	AID239486; AID33928
RNA-directed RNA polymerase		IC50 (µMol)	1.9000	0.0190	2.5279	8.8000	AID86858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	EC50 (µMol)	0.3000	0.0026	0.5334	1.2020	AID86857
RNA-directed RNA polymerase		EC50 (µMol)	0.3000	0.0018	0.2348	2.8000	AID86857
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A1	Bos taurus (cattle)
response to purine-containing compound	Adenosine receptor A1	Bos taurus (cattle)
synaptic transmission, dopaminergic	Adenosine receptor A2a	Homo sapiens (human)
response to amphetamine	Adenosine receptor A2a	Homo sapiens (human)
regulation of DNA-templated transcription	Adenosine receptor A2a	Homo sapiens (human)
phagocytosis	Adenosine receptor A2a	Homo sapiens (human)
apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
cellular defense response	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, cholinergic	Adenosine receptor A2a	Homo sapiens (human)
central nervous system development	Adenosine receptor A2a	Homo sapiens (human)
blood coagulation	Adenosine receptor A2a	Homo sapiens (human)
sensory perception	Adenosine receptor A2a	Homo sapiens (human)
locomotory behavior	Adenosine receptor A2a	Homo sapiens (human)
blood circulation	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A2a	Homo sapiens (human)
response to xenobiotic stimulus	Adenosine receptor A2a	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of glutamate secretion	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmission	Adenosine receptor A2a	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A2a	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A2a	Homo sapiens (human)
response to caffeine	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of urine volume	Adenosine receptor A2a	Homo sapiens (human)
vasodilation	Adenosine receptor A2a	Homo sapiens (human)
eating behavior	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of vascular permeability	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of neuron apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleep	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of alpha-beta T cell activation	Adenosine receptor A2a	Homo sapiens (human)
astrocyte activation	Adenosine receptor A2a	Homo sapiens (human)
neuron projection morphogenesis	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of protein secretion	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
regulation of mitochondrial membrane potential	Adenosine receptor A2a	Homo sapiens (human)
membrane depolarization	Adenosine receptor A2a	Homo sapiens (human)
regulation of calcium ion transport	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
inhibitory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
prepulse inhibition	Adenosine receptor A2a	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Homo sapiens (human)
protein binding	Adenosine receptor A2a	Homo sapiens (human)
calmodulin binding	Adenosine receptor A2a	Homo sapiens (human)
lipid binding	Adenosine receptor A2a	Homo sapiens (human)
enzyme binding	Adenosine receptor A2a	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Adenosine receptor A2a	Homo sapiens (human)
identical protein binding	Adenosine receptor A2a	Homo sapiens (human)
protein-containing complex binding	Adenosine receptor A2a	Homo sapiens (human)
alpha-actinin binding	Adenosine receptor A2a	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
intermediate filament	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
membrane	Adenosine receptor A2a	Homo sapiens (human)
dendrite	Adenosine receptor A2a	Homo sapiens (human)
axolemma	Adenosine receptor A2a	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A2a	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
neuronal cell body	Adenosine receptor A2a	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A2a	Homo sapiens (human)
glutamatergic synapse	Adenosine receptor A2a	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (93)

Assay ID	Title	Year	Journal	Article
AID237857	Oral bioavailability in rat	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID245909	Cytotoxicity against HB-1 cells in an MTS-based assay	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID299924	Cytotoxicity against Huh7 cells after 24 hrs by MTS assay	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine.
AID31854	Inhibition of [3H]CHA (N6-cyclohexyl adenosine) to rat brain membrane Adenosine A1 receptor	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID634090	Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID340156	Antitumor activity against human MCF7 cells after 48 hrs by MTS assay	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID673224	Cytotoxicity against human HuH7 cells assessed as cell viability at 0.5 uM after 3 days by CellTiter Glo assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus.
AID673222	Antiviral activity at Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication at 0.5 uM after 3 days by renilla luciferase reporter gene assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus.
AID634091	Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID545678	Antiviral activity against at 0.3 MOI Dengue virus 2 infected in human A549 cells assessed as level of E protein after 48 hrs by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.
AID662447	Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID573112	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID658632	Oral bioavailability in rat	2012	Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10	Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.
AID634089	Cytotoxicity against human HuH7 cells infected with HCV1b assessed as cell viability at 10 uM after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID410593	Antiviral activity against HCV in ET cells assessed as activity of luciferase reporter by subgenomic RNA replicon assay	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID246255	Inhibition of hepatitis C virus RNA replication in a subgenomic replicon cell line	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Synthesis of 9-(2-beta-C-methyl-beta-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication.
AID662514	Oral bioavailability in rat	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID340154	Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID237085	Half-life in rats	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID410597	Selectivity index, EC50 for HCV to IC50 for ET cells	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID546790	Antiviral activity against Hepatitis C virus genotype 1a in luciferase encoding genotype 1a replicons after 3 days by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
AID296868	Activation of prodrug to corresponding nucleoside triphosphate in Sprague-Dawley rat hepatocytes at 25 uM after 2 hrs	2007	Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16	Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection.
AID236601	Cmax value in rats	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID299922	Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 24 hrs by ribonuclease protection assay	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine.
AID662449	Stability of the compound assessed as compound remaining at 10 uM after 60 mins in presence of bovine adenosine deaminase	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID248027	In vitro inhibitory activity against human colon carcinoma HT-29 cell line	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID233377	Inhibitory selectivity at Adenosine 2A receptor compared to Adenosine 1 receptor.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID243038	Relative affinities against adenosine A2A and A1 receptors (ratio of KiA2A/KiA1)	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID233379	Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 2A receptor.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID662446	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID326174	Antiviral activity against Hepatitis C virus 1b after 3 days	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID255673	Effective concentration required to reduce Hepatitis C virus	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides.
AID545677	Cytotoxicity against human A549 cells assessed as intracellular ATP level by Celltiter-Glo luminescent assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Inhibition of dengue virus RNA synthesis by an adenosine nucleoside.
AID262678	Antiviral activity against BVDV NADL in MDBK cells	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.
AID634088	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction in luciferase activity at 10 uM after 3 days	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID247910	In vitro inhibitory activity against human leukemia K562IU cell line	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID33491	Selectivity towards Adenosine A3 receptor to Adenosine A2A receptor	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID573110	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID239486	Displacement of [3H]CGS-21680 binding to adenosine A2A receptors of bovine striatal membranes	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID33494	Displacement of [3H](R)-PIA from Adenosine A3 receptor of rat testis membrane with 150 nM DPCPX at 10e-5 M	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID573106	Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID248110	In vitro inhibitory activity against human myelogenous leukemia K562 cell line	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID315592	Cytotoxicity against human Huh7 cells harboring con1 replicon after 3 days by MTT assay	2008	Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3	Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino)vinyl]purine nucleosides.
AID573108	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1638600	Antiviral activity against West Nile virus	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID262680	Selectivity index (CC50/EC50) for inhibition of BVDV NADL in MDBK cells	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.
AID662448	Inhibition of HCV genotype 1b NS5B after 90 mins	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID340155	Antitumor activity against human HT29 cells after 48 hrs by MTS assay	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID326175	Cytotoxicity against human Huh7 cells after 3 days by MTT method	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID244278	Percent displacement of [125I]AB-MECA binding to adenosine A3 receptors of bovine cortical membranes at 0.00005 M	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID491244	Cytotoxicity against human Huh7 cells after 3 days by WST-1 assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-hepatitis C virus (HCV) activity of 3'-C-substituted-methyl pyrimidine and purine nucleosides.
AID35021	Affinity to Adenosine A2A receptor of rat brain striatum using [3H]-CGS- 21680	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID237656	Clearance in rats when administered at a dose of 1 mg/kg i.v. and 2 mg/mL p.o.	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID261902	Cytotoxicity against Huh7 cells by MTS assay	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.
AID432569	Antiviral activity against HCV by viral replicon assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.
AID239456	Displacement of [3H]DPCPX binding to adenosine A1 receptors of bovine cortical membranes	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID326173	Cytostatic activity in human HeLa S3 cells assessed as inhibition of cell growth after 48 hrs by XTT assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Synthesis, cytostatic and anti-HCV activity of 6-(N-substituted aminomethyl)-, 6-(O-substituted hydroxymethyl)- and 6-(S-substituted sulfanylmethyl)purine nucleosides.
AID86858	Inhibition HCV NS5B-mediated RNA synthesis	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID246173	Inhibition of HCV RNA replication in a subgenomic bicistronic replicon assay in HB-1 cells	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID86857	Inhibition HCV RNA replication	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID432564	Antiviral activity against HCV assessed as inhibition of viral replicon replication in human Huh5-2 cells	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.
AID299923	Antiviral activity against HCV genotype 1b in Huh7 cells assessed as inhibition of viral RNA replication after 72 hrs by ribonuclease protection assay	2007	Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15	Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine.
AID33928	Inhibitory activity at Adenosine A2A receptor by inhibition of [3H]-CGS- 21680 binding to bovine striatal membranes.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID261901	Antiviral activity against HCV replication	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.
AID573107	Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID262679	Cytotoxicity against MDBK cells	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.
AID432565	Cytotoxicity against human Huh5-2 cells	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.
AID262697	Antiviral activity against VP32947-resistant BVDV in MDBK cells	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.
AID673229	Antiviral activity at Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication at 0.5 uM after 3 days by quantitative RT-PCR analysis	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus.
AID33019	Selectivity for Adenosine A2A over Adenosine A1 receptor	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID236960	Tmax value in rats	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID410595	Cytotoxicity against ET cells	2009	Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1	Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.
AID233378	Inhibitory selectivity at Adenosine A3 receptor compared to Adenosine 1 receptor.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID32002	Inhibitory activity at Adenosine A1 receptor by inhibition of [3H]CHA binding to bovine brain cortical membranes.	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID573111	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID662513	Plasma clearance in rat	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID247671	Compound was tested for the inhibition of HCV NS5B-mediated RNA synthesis	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
AID243033	Relative affinities for adenosine A3 and A1 receptors (ratio of KiA3/KiA1)	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID248043	In vitro inhibitory activity against human breast carcinoma MCF-7 cell line	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
AID255627	Cytotoxic concentration required to reduce the rRNA level of hepatitis C virus	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides.
AID1502482	Antiviral activity against Dengue virus 2 New Guinea assessed as inhibition of virus induced cytopathic effect by neutral red dye uptake assay	2017	ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9	Anchimerically Activatable Antiviral ProTides.
AID491243	Antiviral activity against HCV genotype1 infected in human Huh7 cells assessed as reduction of viral replication by steady-Glo luciferase assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-hepatitis C virus (HCV) activity of 3'-C-substituted-methyl pyrimidine and purine nucleosides.
AID573109	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID33490	Selectivity for Adenosine A3 over Adenosine A1 receptor	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.
AID315591	Antiviral activity against HCV 1b Con1 replicon in Huh7 cells	2008	Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3	Synthesis, cytostatic, and antiviral activity of novel 6-[2-(dialkylamino)ethyl]-, 6-(2-alkoxyethyl)-, 6-[2-(alkylsulfanyl)ethyl]-, and 6-[2-(dialkylamino)vinyl]purine nucleosides.
AID546789	Antiviral activity against Hepatitis C virus genotype 1b in luciferase encoding genotype 1b replicons after 3 days by luciferase reporter assay	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
AID245982	Cytotoxicity concentration to inhibit hepatitis C virus RNA replication in a subgenomic replicon cell line	2005	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3	Synthesis of 9-(2-beta-C-methyl-beta-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication.
AID340153	Antitumor activity against human K562 cells after 48 hrs by MTS assay	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID573105	Cytotoxicity against human HuH6 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID634092	Therapeutic index, ratio of CC50 for human HuH7 cells infected with HCV1b to EC50 for HCV genotype 1b	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID33330	Inhibitory activity against Adenosine A3 receptor by inhibition of [3H](R)-PIA binding to rat testis membranes	1998	Journal of medicinal chemistry, May-07, Volume: 41, Issue:10	2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID243039	Relative affinities for adenosine A2A and A3 receptors (ratio of KiA2A/KiA3)	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
AID262698	Selectivity index (CC50/EC50) for inhibition of VP32947-resistant BVDV in MDBK cells	2006	Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8	Synthesis and anti-BVDV activity of acridones as new potential antiviral agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (2.70)	18.2507
2000's	17 (45.95)	29.6817
2010's	17 (45.95)	24.3611
2020's	2 (5.41)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (5.41%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (94.59%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbamates [no description available]	2.15	1	amino-acid anion
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	2.04	1
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	2.15	1	carboxamidine; guanidines; one-carbon compound
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	2.44	2	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
cytidine [no description available]	2.54	2	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
tubercidin Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.	2.86	3	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.15	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
cordycepin [no description available]	2.02	1	3'-deoxyribonucleoside; adenosines	antimetabolite; nucleoside antibiotic
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.1	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
2-chloroadenosine 5-chloroformycin A: structure given in first source	2.41	2	purine nucleoside
thiophene-2-carboxylate thiophene-2-carboxylic acid : A thiophenecarboxylic acid in which the carboxy group is located at position 2.	2.04	1	thiophenecarboxylic acid
hyaluronoglucosaminidase kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source	2.04	1	purine nucleoside
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.02	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
ribavirin Rebetron: Rebetron is tradename	2.79	3	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.05	1	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.04	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
lamivudine [no description available]	2.05	1	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	9.94	10	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
n(6)-benzyladenosine N(6)-benzyladenosine: RN given refers to parent cpd	2.04	1
phenylisopropyladenosine [no description available]	2.41	2	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
2'-fluoro-2'-deoxyadenosine [no description available]	2.02	1
n(6)-phenyladenosine [no description available]	2.04	1	purine nucleoside
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.02	1	methyladenosine
2'-o-methyladenosine cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.	2.02	1	adenosines; ether	fungal metabolite
3'-fluoro-3'-deoxyadenosine 3'-fluoro-3'-deoxyadenosine: structure given in first source	2.02	1
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	2.41	2	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
2-chloro-n(6)cyclopentyladenosine 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors	2.42	2
3'-deoxycytidine [no description available]	3.17	1
2'-o-methylcytidine [no description available]	3.17	1	methylcytidine
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	2.41	2	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
4'-azidocytidine 4'-azidocytidine: antiviral; structure in first source	3.56	2	N-glycosyl compound
3'-c-methyladenosine 3'-C-methyladenosine: structure in first source	3.27	6
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	3.17	5
2'-c-methyluridine 2'-C-methyluridine: structure in first source	2.07	1
n(6)-cyclopentyladenosine [no description available]	2.7	3
telaprevir [no description available]	2.75	3	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
mk 0608 7-deaza-2'-C-methyladenosine: an antiviral agent	3.48	7
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source	2.02	1
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.04	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer [no description available]	2.41	2
valopicitabine valopicitabine: prodrug of 2'-C-methylcytidine; an anti-hepatitis C virus agent; structure in first source	2.03	1
n(6)-cyclohexyladenosine N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist	2.42	2
biln 2061 BILN 2061: a macrocyclic NS3 protease inhibitor and antiviral agent; structure in first source	2.45	2
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.04	1	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
alisporivir alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source	2.04	1	homodetic cyclic peptide	anticoronaviral agent
hcv 796 HCV 796: inhibits HCV RdRp; structure in first source	3.85	3
bms-650032 asunaprevir: an NS3 protease inhibitor against hepatitis C virus	2.15	1	oligopeptide
bms-790052 daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.	2.15	1	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
nitd008 NITD008: inhibits enterovirus 71	2.05	1
sofosbuvir Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	2.15	1	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.1	1
2'-o-methylguanosine 2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.	3.54	2	methylguanosine	metabolite
2'-deoxy-2'-fluoroguanosine 2'-deoxy-2'-fluoroguanosine: has activity in human respiratory epithelial cells against both influenza A & B viruses	2.02	1
3-deoxyguanosine 3'-deoxyguanosine : A 3'-deoxyribonucleoside having guanine as the nucleobase.	3.54	2	3'-deoxyribonucleoside; guanosines	EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor

Condition	Relationship Strength	Studies
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	3.9	4
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	8.9	4
Encephalitis, West Nile Fever [description not available]	2.21	1
West Nile Fever A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71)	2.21	1
Congenital Zika Syndrome [description not available]	2.66	2
Innate Inflammatory Response [description not available]	2.25	1
Nervous System Disorders [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	7.66	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.25	1
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	2.25	1
Acute Myelogenous Leukemia [description not available]	2.11	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.11	1
Kahler Disease [description not available]	3.04	1
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	3.04	1
Chronic Hepatitis C [description not available]	2.15	1
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	2.15	1

2'-c-methyladenosine

Description

Cross-References

Synonyms (32)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (50)

Molecular Functions (9)

Ceullar Components (12)

Bioassays (93)

Research

Studies (37)

Market Indicators

Research Demand Index: 19.24

Study Types

2'-c-methyladenosine

Description

Cross-References

Synonyms (32)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (50)

Molecular Functions (9)

Ceullar Components (12)

Bioassays (93)

Research

Studies (37)

Market Indicators

Research Demand Index: 19.24

Study Types

Related Drugs (54)

Related Conditions (16)